Industry news

• Rusnano Fund stimulates demand for nano products

  08 April 2013 Venture News

  The Government of Kaluga Region and Rusnano’s Fund for Infrastructure and Educational Programs (FIEP) have launched a programme to stimulate demand for nanotech products in the region, the press service of the fund reports.
   

• Here Are 3 Things Big Pharma Must Do To Survive - Joseph Jimenez

  04 April 2013 Max Nisen, Business Insider

  After years of relative stability and high profits, things aren't looking particularly rosy for the pharmaceutical industry. Blockbuster drugs are losing patent protection, R&D efforts haven't paid off as hoped, and prices will come under pressure from the Affordable Care Act.

• New Far East medical center may expect equipment from Rusnano or Japanese

  02 April 2013 Marchmont Innovation News

  Rusnano, Russia’s nanotech giant, is ready to join as a co-investor whatever private-public partnership (PPP) may form to equip the new high tech medical center to soon open at Vladivostok-based Far East Federal University (FEFU), the first such center in the Primorsky region in Russia’s Far East

• The revenue of Rusnano nanotech centers in 2012 is 365M RUR

  01 April 2013 Venture-news

  According to Rusnano, the revenue of Russian nanotech centers that were launched in 2012 under the auspices of the Fund for infrastructure and educational programs of Rusnano, JSC totaled 365M RUR. 

• Russian investment vehicle sets sights on innovative drugs

  29 March 2013 Eugene Gerden, Chemistry World

  

  Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.

• U.S. struggles with pharmaceutical goals in Asia trade talks

  29 March 2013 Doug Palmer, Reuters

  The United States is striving to find an appropriate balance in Asia-Pacific free trade talks between providing strong patent and data protections for U.S. drug manufacturers and ensuring poor people have access to medicine, a U.S. trade negotiator said on Thursday.

• GlaxoSmithKline and Abbott to start production in Ukraine

  28 March 2013 The Pharma Letter

  UK pharma giant GlaxoSmithKline and the USA’s Abbott are considering launching production of their drugs in Ukraine at the facilities of Indar, one of Ukraine’s largest pharmaceutical producers, owned by the state.

• Eisai joins trend to enter Russian pharma market, with Halaven launch

  27 March 2013 The Pharma Letter

  Japanese drug major Eisai unit, has announced it is expanding its operations by establishing a new sales and marketing operation in Russia, a market that has seen a great deal attention from multinational pharmaceutical companies in recent times.

• Amendments to drug registration law in Russia: Implications for the future

  26 March 2013 Kavita Rainova, IHS Healthcare and Pharma blog

  The eagerly awaited draft amendments to the federal law, as well as Article 333.32.1, part two of the tax code of the Russian Federation, were published for consultation by the country’s Ministry of Health in late January this year. The amendments proved to be a mixed bag.

• Expert team publishes International Declaration after Open Innovations International Forum

  22 March 2013

  The panel consisting of the well-known venture capitalists, managers of the world-leading universities, market analysts, and representatives of Russian development institutes prepared the International Declaration on the Forum "Open Innovation 2012".